Skip to main content
BCYC logo

BCYC · Bicycle Therapeutics PLC

Track BCYC — free
$3.06 -0.05 (-1.61%)
Market Cap
$213.79M
Shares
70.09M
Volume · Nov 19 464.81K Avg daily vol (3M) 435.58K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.05 Open$3.13 Day$3.04–3.18 52W close$3.05–7.52 Avg vol 30d426K Short int3.9M · 5.5% of shares · 8.4d Short vol33% Last earningsOct 30, 2025 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Latest documents

2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Reprioritization and 30% workforce cut target 50% lower expenses

Bicycle Therapeutics posted a net loss of $121.6 million for the nine months ended September 30, 2026. In March 2026 it announced a strategic reprioritization and a workforce reduction of approximately 30%, expected to reduce annual operating expenses by approximately 50%. It held $469.9 million in cash and cash equivalents as of September 30, 2026, which it believes funds operations for at least 12 months.

Revenue $34.06M ▲ 190.2% Net loss $10.48M Diluted EPS -$0.15
Read from the MD&A section
6 source passages
Our net losses were $10.5 million and $121.6 million for the three and nine months ended September 30, 2026. In March 2026, we announced the strategic reprioritization of our clinical portfolio to focus on our promising pipeline of next-generation therapeutics, including nuzefatide pevedotin as well as next-generation Bicycle conjugates, including BRC molecules. we announced a workforce reduction of approximately 30% of our workforce. Together, the workforce reduction and strategic reprioritization are expected to reduce our annual operating expenses by approximately 50% based on our current plans. As of September 30, 2026, we had cash and cash equivalents of $469.9 million. we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing of this Quarterly Report. Open the document at this passage
Oct 29
Current report 8-K
Nuzefatide earns FDA orphan designation for pancreatic cancer

Bicycle Therapeutics reported that nuzefatide pevedotin was granted FDA Orphan Drug Designation for pancreatic cancer in September 2026. Cash and cash equivalents were $469.9 million as of September 30, 2026, with expected cash runway into 2030.

Financial results
4 source passages
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results Nuzefatide pevedotin (nuzefatide), a potentially first-in-class EphA2 targeting Bicycle Drug Conjugate (BDC), was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. In September 2026, the FDA granted nuzefatide ODD for the treatment of pancreatic cancer. Cash and cash equivalents of $469.9 million as of September 30, 2026, with expected cash runway into 2030 Open the document at this passage
Jul 30
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $629K ▼ 78.5% Net loss $50.33M Diluted EPS -$0.72
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$83.53M
Trailing 12 months
Net income (TTM)
−$141.79M
Trailing 12 months
Revenue growth YoY
+190.2%
Year over year
Operating margin
-189.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-81.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$469.21M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.0%
Year over year · more shares
Price change (1Y)
-51.9%
Trailing year
Short interest
5.5%
Latest settlement · 8.4 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −30%
below
Price vs 50-day avg −16%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −33%
trailing
YTD return −57%
this year
Relative strength −27%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +8 funds added
Insider flow Distributing
Net -$57.4K over 90 days · 100% sells
Short interest Rising
5.51% of shares out · ▲ +11.7% MoM · 8.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
92 holders — near 3-yr low, contrarian setup
Squeeze score 70
high risk · 0–100
Fundamentals
Weak
Revenue growth +106%
Y/Y
EPS growth −9%
Y/Y
Free cash flow $-252.0M
Quant / Vol
risk profile
Very High
Volatility 51%
annualized · 1-yr
Max drawdown −59%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−30% Bearish
Price vs 50-day avg
−16% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +8 funds added
Insider flow Distributing
Net -$57.4K over 90 days · 100% sells
Short interest Rising
5.51% of shares out · ▲ +11.7% MoM · 8.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
92 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $3 Now $3 · 0% Range high $8
vs 200-day avg -30% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BCYC
Bicycle Therapeutics PLC
this stock
$213.79M -56.9% +105.8% — 5.5%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
92
% held
50.8%
Net QoQ
-1.7M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
23
View
Short & Settlement
Short Interest Rising
Shares short
3.9M
Days to cover
8.4d
Change
+405.6K sh
View
Short Volume
Short vol %
33%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
6.2K
Value
$21.9K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
32.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$57.4K
Buyers / Sellers
0 / 5
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$72.6M
Net income (FY)
$-219.0M
EPS diluted
$-3.16
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
17

Bicycle Therapeutics posted a net loss of $121.6 million for the nine months ended September 30, 2026. In March 2026 it announced a strategic reprioritization and a workforce reduction of approximately 30%, expected to reduce annual operating expenses by approximately 50%. It held $469.9 million in cash and cash equivalents as of September 30, 2026, which it believes funds operations for at least 12 months.

View
Proposed Sales
Value
$31.2K
Shares
9.0K
Filed
Oct 2, 2026
View
Exempt Offerings
Offering
$555.5M
Filed
Jun 12, 2024
View
Earnings & Events
Webcasts
Last webcast
Oct 30, 2025
View
Investor Relations
Latest news
Bicycle Therapeutics Reports Rece…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
BCYC -11.6% -16.2% -32.7% -16.7% -56.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -6.1% -9.9% -27.0% -11.4% -61.9%
Key facts CIK 1761612 CUSIP 088786108 13F (30d) 102 filings 90 filers Visit website Investor relations